206 related articles for article (PubMed ID: 34325126)
1. Simultaneous inhibition of PFKFB3 and GLS1 selectively kills KRAS-transformed pancreatic cells.
Ozcan SC; Mutlu A; Altunok TH; Gurpinar Y; Sarioglu A; Guler S; Muchut RJ; Iglesias AA; Celikler S; Campbell PM; Yalcin A
Biochem Biophys Res Commun; 2021 Sep; 571():118-124. PubMed ID: 34325126
[TBL] [Abstract][Full Text] [Related]
2. p38γ MAPK Is Essential for Aerobic Glycolysis and Pancreatic Tumorigenesis.
Wang F; Qi XM; Wertz R; Mortensen M; Hagen C; Evans J; Sheinin Y; James M; Liu P; Tsai S; Thomas J; Mackinnon A; Dwinell M; Myers CR; Bartrons Bach R; Fu L; Chen G
Cancer Res; 2020 Aug; 80(16):3251-3264. PubMed ID: 32580961
[TBL] [Abstract][Full Text] [Related]
3. Nrf2 Activation Sensitizes K-Ras Mutant Pancreatic Cancer Cells to Glutaminase Inhibition.
Hamada S; Matsumoto R; Tanaka Y; Taguchi K; Yamamoto M; Masamune A
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33672789
[TBL] [Abstract][Full Text] [Related]
4. Targeting glutaminolysis has antileukemic activity in acute myeloid leukemia and synergizes with BCL-2 inhibition.
Jacque N; Ronchetti AM; Larrue C; Meunier G; Birsen R; Willems L; Saland E; Decroocq J; Maciel TT; Lambert M; Poulain L; Hospital MA; Sujobert P; Joseph L; Chapuis N; Lacombe C; Moura IC; Demo S; Sarry JE; Recher C; Mayeux P; Tamburini J; Bouscary D
Blood; 2015 Sep; 126(11):1346-56. PubMed ID: 26186940
[TBL] [Abstract][Full Text] [Related]
5. Glutaminase-1 stimulates the proliferation, migration, and survival of human endothelial cells.
Peyton KJ; Liu XM; Yu Y; Yates B; Behnammanesh G; Durante W
Biochem Pharmacol; 2018 Oct; 156():204-214. PubMed ID: 30144404
[TBL] [Abstract][Full Text] [Related]
6. Oncogenic ERBB2 aberrations and KRAS mutations cooperate to promote pancreatic ductal adenocarcinoma progression.
Li Z; Shao C; Liu X; Lu X; Jia X; Zheng X; Wang S; Zhu L; Li K; Pang Y; Xie F; Lu Y; Wang Y
Carcinogenesis; 2020 Mar; 41(1):44-55. PubMed ID: 31046123
[TBL] [Abstract][Full Text] [Related]
7. Glutamine metabolism via glutaminase 1 in autosomal-dominant polycystic kidney disease.
Soomro I; Sun Y; Li Z; Diggs L; Hatzivassiliou G; Thomas AG; Rais R; Parker SJ; Slusher BS; Kimmelman AC; Somlo S; Skolnik EY
Nephrol Dial Transplant; 2018 Aug; 33(8):1343-1353. PubMed ID: 29420817
[TBL] [Abstract][Full Text] [Related]
8. Molecular basis for the differential use of glucose and glutamine in cell proliferation as revealed by synchronized HeLa cells.
Colombo SL; Palacios-Callender M; Frakich N; Carcamo S; Kovacs I; Tudzarova S; Moncada S
Proc Natl Acad Sci U S A; 2011 Dec; 108(52):21069-74. PubMed ID: 22106309
[TBL] [Abstract][Full Text] [Related]
9. Increased 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3 activity in response to EGFR signaling contributes to non-small cell lung cancer cell survival.
Lypova N; Telang S; Chesney J; Imbert-Fernandez Y
J Biol Chem; 2019 Jul; 294(27):10530-10543. PubMed ID: 31126985
[TBL] [Abstract][Full Text] [Related]
10. Inhibiting glutaminase in acute myeloid leukemia: metabolic dependency of selected AML subtypes.
Matre P; Velez J; Jacamo R; Qi Y; Su X; Cai T; Chan SM; Lodi A; Sweeney SR; Ma H; Davis RE; Baran N; Haferlach T; Su X; Flores ER; Gonzalez D; Konoplev S; Samudio I; DiNardo C; Majeti R; Schimmer AD; Li W; Wang T; Tiziani S; Konopleva M
Oncotarget; 2016 Nov; 7(48):79722-79735. PubMed ID: 27806325
[TBL] [Abstract][Full Text] [Related]
11. Combination therapy with BPTES nanoparticles and metformin targets the metabolic heterogeneity of pancreatic cancer.
Elgogary A; Xu Q; Poore B; Alt J; Zimmermann SC; Zhao L; Fu J; Chen B; Xia S; Liu Y; Neisser M; Nguyen C; Lee R; Park JK; Reyes J; Hartung T; Rojas C; Rais R; Tsukamoto T; Semenza GL; Hanes J; Slusher BS; Le A
Proc Natl Acad Sci U S A; 2016 Sep; 113(36):E5328-36. PubMed ID: 27559084
[TBL] [Abstract][Full Text] [Related]
12. Small-molecule inhibition of 6-phosphofructo-2-kinase activity suppresses glycolytic flux and tumor growth.
Clem B; Telang S; Clem A; Yalcin A; Meier J; Simmons A; Rasku MA; Arumugam S; Dean WL; Eaton J; Lane A; Trent JO; Chesney J
Mol Cancer Ther; 2008 Jan; 7(1):110-20. PubMed ID: 18202014
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of 6-phosphofructo-2-kinase (PFKFB3) suppresses glucose metabolism and the growth of HER2+ breast cancer.
O'Neal J; Clem A; Reynolds L; Dougherty S; Imbert-Fernandez Y; Telang S; Chesney J; Clem BF
Breast Cancer Res Treat; 2016 Nov; 160(1):29-40. PubMed ID: 27613609
[TBL] [Abstract][Full Text] [Related]
14. Aurora A kinase and its activator TPX2 are potential therapeutic targets in KRAS-induced pancreatic cancer.
Gomes-Filho SM; Dos Santos EO; Bertoldi ERM; Scalabrini LC; Heidrich V; Dazzani B; Levantini E; Reis EM; Bassères DS
Cell Oncol (Dordr); 2020 Jun; 43(3):445-460. PubMed ID: 32193808
[TBL] [Abstract][Full Text] [Related]
15. Critical role of oncogenic KRAS in pancreatic cancer (Review).
Liu J; Ji S; Liang C; Qin Y; Jin K; Liang D; Xu W; Shi S; Zhang B; Liu L; Liu C; Xu J; Ni Q; Yu X
Mol Med Rep; 2016 Jun; 13(6):4943-9. PubMed ID: 27121414
[TBL] [Abstract][Full Text] [Related]
16. Estradiol stimulates glucose metabolism via 6-phosphofructo-2-kinase (PFKFB3).
Imbert-Fernandez Y; Clem BF; O'Neal J; Kerr DA; Spaulding R; Lanceta L; Clem AL; Telang S; Chesney J
J Biol Chem; 2014 Mar; 289(13):9440-8. PubMed ID: 24515104
[TBL] [Abstract][Full Text] [Related]
17. Dependence on the Pyrimidine Biosynthetic Enzyme DHODH Is a Synthetic Lethal Vulnerability in Mutant KRAS-Driven Cancers.
Koundinya M; Sudhalter J; Courjaud A; Lionne B; Touyer G; Bonnet L; Menguy I; Schreiber I; Perrault C; Vougier S; Benhamou B; Zhang B; He T; Gao Q; Gee P; Simard D; Castaldi MP; Tomlinson R; Reiling S; Barrague M; Newcombe R; Cao H; Wang Y; Sun F; Murtie J; Munson M; Yang E; Harper D; Bouaboula M; Pollard J; Grepin C; Garcia-Echeverria C; Cheng H; Adrian F; Winter C; Licht S; Cornella-Taracido I; Arrebola R; Morris A
Cell Chem Biol; 2018 Jun; 25(6):705-717.e11. PubMed ID: 29628435
[TBL] [Abstract][Full Text] [Related]
18. Eicosapentaenoic Acid Inhibits
Chiu CF; Hsu MI; Yeh HY; Park JM; Shen YS; Tung TH; Huang JJ; Wu HT; Huang SY
Biomolecules; 2021 Mar; 11(3):. PubMed ID: 33801246
[TBL] [Abstract][Full Text] [Related]
19. Loss of Somatostatin Receptor Subtype 2 Promotes Growth of KRAS-Induced Pancreatic Tumors in Mice by Activating PI3K Signaling and Overexpression of CXCL16.
Chalabi-Dchar M; Cassant-Sourdy S; Duluc C; Fanjul M; Lulka H; Samain R; Roche C; Breibach F; Delisle MB; Poupot M; Dufresne M; Shimaoka T; Yonehara S; Mathonnet M; Pyronnet S; Bousquet C
Gastroenterology; 2015 Jun; 148(7):1452-65. PubMed ID: 25683115
[TBL] [Abstract][Full Text] [Related]
20. Use of DNA-alkylating pyrrole-imidazole polyamides for anti-cancer drug sensitivity screening in pancreatic ductal adenocarcinoma.
Tsujimoto A; Matsuo N; Lai X; Inoue T; Yoda H; Lin J; Shinozaki Y; Watanabe T; Koshikawa N; Takatori A; Nagase H
Cancer Med; 2023 Mar; 12(5):5821-5832. PubMed ID: 36262061
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
